Specifically, female patients with stage IV NSCLC and high CXCR4 expression experienced notably poorer clinical outcomes, with a median overall survival of only 1.6 months, in contrast to 6.4 months for low expressors. The gene discussed is CXCR4; the disease is non-small cell lung carcinoma.